Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

Who is this study for? Patients with Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia
What treatments are being studied? PXL-330 Platinum Device for Crosslinking with Peschke Riboflavin Solution
Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Healthy Volunteers: f
View:

‣ Subjects who have one or both eyes that meet criteria 1 and 1 or more of the following criteria will be considered candidates for this study:

• 10 years of age or older 2. Presence of central or inferior steepening 3. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration 4. Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as:

⁃ Fleischer ring

⁃ Vogt's striae

⁃ Decentered corneal apex

⁃ Munson's sign

⁃ Apical Corneal scarring consistent with Bowman's breaks

⁃ Scissoring of the retinoscopic reflex

⁃ Crab-claw appearance on topography 5. Steepest keratometry (Kmax) value ≥ 47.20 D 6. I-S keratometry difference \> 1.5 D on the Pentacam map or topography map 7. Posterior corneal elevation \>16 microns 8. Thinnest corneal point \>300 microns 9. Contact Lens Wearers Only:

‣ a. Removal of contact lenses for the required period of time prior to the screening refraction: Contact Lens Type Minimum Discontinuation Time Soft or Scleral 3 days Rigid gas permeable 2 weeks

Locations
United States
California
Goodman Eye Center
RECRUITING
San Francisco
Time Frame
Start Date: 2019-10-19
Estimated Completion Date: 2029-10-19
Participants
Target number of participants: 500
Treatments
Experimental: Pulsed, accelerated
4 mW, 10-15 sec on, 10-15sec off, 45 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Experimental: Pusled, accelerated
8 mW, 10-15 sec on, 10-15 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Related Therapeutic Areas
Sponsors
Leads: Goodman Eye Center

This content was sourced from clinicaltrials.gov